SOPHiA GENETICS (SOPH) Competitors

SOPHiA GENETICS logo
$7.44 -0.77 (-9.38%)
Closing price 04:00 PM Eastern
Extended Trading
$7.44 -0.01 (-0.07%)
As of 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SOPH vs. SDGR, CERT, TDOC, GDRX, and HSTM

Should you buy SOPHiA GENETICS stock or one of its competitors? SOPHiA GENETICS's main competitors and comparable companies include Schrodinger (SDGR), Certara (CERT), Teladoc Health (TDOC), GoodRx (GDRX), and HealthStream (HSTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does SOPHiA GENETICS compare to Schrodinger?

Schrodinger (NASDAQ:SDGR) and SOPHiA GENETICS (NASDAQ:SOPH) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

SOPHiA GENETICS has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrodinger$269.20M8.10-$103.26M-$0.79N/A
SOPHiA GENETICS$77.27M8.91-$79M-$1.09N/A

Schrodinger presently has a consensus price target of $26.67, suggesting a potential downside of 9.70%. SOPHiA GENETICS has a consensus price target of $10.00, suggesting a potential upside of 21.80%. Given SOPHiA GENETICS's stronger consensus rating and higher probable upside, analysts plainly believe SOPHiA GENETICS is more favorable than Schrodinger.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Schrodinger
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38
SOPHiA GENETICS
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Schrodinger has a net margin of -22.02% compared to SOPHiA GENETICS's net margin of -89.18%. Schrodinger's return on equity of -18.12% beat SOPHiA GENETICS's return on equity.

Company Net Margins Return on Equity Return on Assets
Schrodinger-22.02% -18.12% -9.07%
SOPHiA GENETICS -89.18%-128.69%-44.73%

In the previous week, Schrodinger had 6 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 13 mentions for Schrodinger and 7 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 0.68 beat Schrodinger's score of 0.64 indicating that SOPHiA GENETICS is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Schrodinger
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
SOPHiA GENETICS
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

79.1% of Schrodinger shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 10.1% of Schrodinger shares are held by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Schrodinger has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

Summary

Schrodinger beats SOPHiA GENETICS on 10 of the 16 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Certara?

SOPHiA GENETICS (NASDAQ:SOPH) and Certara (NASDAQ:CERT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Certara has a net margin of -16.14% compared to SOPHiA GENETICS's net margin of -89.18%. Certara's return on equity of 3.36% beat SOPHiA GENETICS's return on equity.

Company Net Margins Return on Equity Return on Assets
SOPHiA GENETICS-89.18% -128.69% -44.73%
Certara -16.14%3.36%2.31%

SOPHiA GENETICS currently has a consensus target price of $10.00, suggesting a potential upside of 21.80%. Certara has a consensus target price of $9.92, suggesting a potential downside of 14.29%. Given SOPHiA GENETICS's stronger consensus rating and higher possible upside, equities research analysts plainly believe SOPHiA GENETICS is more favorable than Certara.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOPHiA GENETICS
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Certara
1 Sell rating(s)
7 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.38

Certara has higher revenue and earnings than SOPHiA GENETICS. Certara is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOPHiA GENETICS$77.27M8.91-$79M-$1.09N/A
Certara$425.76M4.15-$1.60M-$0.42N/A

31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 74.0% of Certara shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 1.1% of Certara shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

SOPHiA GENETICS has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Certara has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

In the previous week, SOPHiA GENETICS had 4 more articles in the media than Certara. MarketBeat recorded 7 mentions for SOPHiA GENETICS and 3 mentions for Certara. Certara's average media sentiment score of 0.96 beat SOPHiA GENETICS's score of 0.68 indicating that Certara is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SOPHiA GENETICS
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Certara
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Certara beats SOPHiA GENETICS on 11 of the 17 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Teladoc Health?

SOPHiA GENETICS (NASDAQ:SOPH) and Teladoc Health (NYSE:TDOC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

In the previous week, Teladoc Health had 3 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 10 mentions for Teladoc Health and 7 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 0.68 beat Teladoc Health's score of 0.65 indicating that SOPHiA GENETICS is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SOPHiA GENETICS
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Teladoc Health
5 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

SOPHiA GENETICS presently has a consensus target price of $10.00, suggesting a potential upside of 21.80%. Teladoc Health has a consensus target price of $8.53, suggesting a potential downside of 3.09%. Given SOPHiA GENETICS's stronger consensus rating and higher probable upside, equities analysts plainly believe SOPHiA GENETICS is more favorable than Teladoc Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOPHiA GENETICS
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Teladoc Health
2 Sell rating(s)
11 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.17

Teladoc Health has a net margin of -6.27% compared to SOPHiA GENETICS's net margin of -89.18%. Teladoc Health's return on equity of -11.63% beat SOPHiA GENETICS's return on equity.

Company Net Margins Return on Equity Return on Assets
SOPHiA GENETICS-89.18% -128.69% -44.73%
Teladoc Health -6.27%-11.63%-5.53%

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 76.8% of Teladoc Health shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Comparatively, 0.7% of Teladoc Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

SOPHiA GENETICS has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Teladoc Health has a beta of 2, indicating that its stock price is 100% more volatile than the broader market.

SOPHiA GENETICS has higher earnings, but lower revenue than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOPHiA GENETICS$77.27M8.91-$79M-$1.09N/A
Teladoc Health$2.47B0.65-$200.32M-$0.86N/A

Summary

Teladoc Health beats SOPHiA GENETICS on 9 of the 16 factors compared between the two stocks.

How does SOPHiA GENETICS compare to GoodRx?

SOPHiA GENETICS (NASDAQ:SOPH) and GoodRx (NASDAQ:GDRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

SOPHiA GENETICS currently has a consensus price target of $10.00, suggesting a potential upside of 21.80%. GoodRx has a consensus price target of $4.15, suggesting a potential upside of 16.57%. Given SOPHiA GENETICS's stronger consensus rating and higher possible upside, analysts plainly believe SOPHiA GENETICS is more favorable than GoodRx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOPHiA GENETICS
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
GoodRx
3 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.08

In the previous week, SOPHiA GENETICS had 1 more articles in the media than GoodRx. MarketBeat recorded 7 mentions for SOPHiA GENETICS and 6 mentions for GoodRx. SOPHiA GENETICS's average media sentiment score of 0.68 beat GoodRx's score of 0.46 indicating that SOPHiA GENETICS is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SOPHiA GENETICS
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
GoodRx
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

SOPHiA GENETICS has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, GoodRx has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market.

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Comparatively, 5.9% of GoodRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

GoodRx has a net margin of 2.07% compared to SOPHiA GENETICS's net margin of -89.18%. GoodRx's return on equity of 7.22% beat SOPHiA GENETICS's return on equity.

Company Net Margins Return on Equity Return on Assets
SOPHiA GENETICS-89.18% -128.69% -44.73%
GoodRx 2.07%7.22%2.53%

GoodRx has higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOPHiA GENETICS$77.27M8.91-$79M-$1.09N/A
GoodRx$785.23M1.55$30.44M$0.0489.00

Summary

GoodRx beats SOPHiA GENETICS on 11 of the 16 factors compared between the two stocks.

How does SOPHiA GENETICS compare to HealthStream?

SOPHiA GENETICS (NASDAQ:SOPH) and HealthStream (NASDAQ:HSTM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

HealthStream has higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than HealthStream, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOPHiA GENETICS$77.27M8.91-$79M-$1.09N/A
HealthStream$304.06M2.82$18.34M$0.7039.96

HealthStream has a net margin of 6.25% compared to SOPHiA GENETICS's net margin of -89.18%. HealthStream's return on equity of 6.37% beat SOPHiA GENETICS's return on equity.

Company Net Margins Return on Equity Return on Assets
SOPHiA GENETICS-89.18% -128.69% -44.73%
HealthStream 6.25%6.37%4.37%

SOPHiA GENETICS presently has a consensus price target of $10.00, indicating a potential upside of 21.80%. HealthStream has a consensus price target of $36.00, indicating a potential upside of 28.71%. Given HealthStream's higher possible upside, analysts plainly believe HealthStream is more favorable than SOPHiA GENETICS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOPHiA GENETICS
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
HealthStream
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20

SOPHiA GENETICS has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, HealthStream has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

In the previous week, SOPHiA GENETICS had 5 more articles in the media than HealthStream. MarketBeat recorded 7 mentions for SOPHiA GENETICS and 2 mentions for HealthStream. SOPHiA GENETICS's average media sentiment score of 0.68 beat HealthStream's score of 0.37 indicating that SOPHiA GENETICS is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SOPHiA GENETICS
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
HealthStream
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 69.6% of HealthStream shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 20.4% of HealthStream shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

HealthStream beats SOPHiA GENETICS on 10 of the 16 factors compared between the two stocks.

Get SOPHiA GENETICS News Delivered to You Automatically

Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SOPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SOPH vs. The Competition

MetricSOPHiA GENETICSHealthcare Technology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$624.18M$1.97B$7.83B$11.75B
Dividend YieldN/A3.89%2.47%4.41%
P/E Ratio-6.8342.1834.3430.11
Price / Sales6.865.088.005.33
Price / CashN/A15.7621.0222.34
Price / Book10.785.774.763.85
Net Income-$79M-$19.09M$3.52B$393.14M
7 Day Performance-0.67%-7.00%-5.34%-4.53%
1 Month Performance10.55%-5.11%-3.61%-5.86%
1 Year Performance72.62%-11.78%0.01%-7.78%

SOPHiA GENETICS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SOPH
SOPHiA GENETICS
3.1116 of 5 stars
$7.44
-9.4%
$10.00
+34.4%
+90.5%$624.18M$90.97MN/A415
SDGR
Schrodinger
1.8661 of 5 stars
$27.18
+3.8%
$25.83
-5.0%
+67.4%$1.93B$255.87MN/A850
CERT
Certara
1.7877 of 5 stars
$10.87
+1.5%
$9.18
-15.5%
+38.9%$1.63B$418.84MN/A1,576
TDOC
Teladoc Health
1.3247 of 5 stars
$8.93
+3.4%
$8.07
-9.6%
+27.3%$1.57B$2.53BN/A5,600
GDRX
GoodRx
3.5931 of 5 stars
$3.49
-1.7%
$4.23
+21.1%
+19.9%$1.22B$796.85M87.27697

Related Companies and Tools


This page (NASDAQ:SOPH) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners